Submitted:
11 July 2023
Posted:
12 July 2023
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Materials and Methods
2.1. Collection and Identification of Pentaclethra macrophylla Stem Bark
2.2. Maceration and Extraction of Plant Material
2.3. Extraction of goat fat from Capra hircus
2.4. Preparation of Lipospheres
2.5. Characterization of Lipospheres
2.5.1. Determination of Particle size and morphology of lipospheres
2.5.2. pH – time dependent analysis
2.5.3. Encapsulation efficiency (EE %)
2.5.4. HPLC method
2.6. FTIR analysis
2.7. In vitro Anti-nociceptive and Anti-inflammatory study
2.7.1. Assay of Membrane Stabilization by Hypotonicity induced hemolysis
2.7.2. Determination of Anti-platelet aggregatory activity
2.8. In-vivo antinociceptive and anti-inflammatory study
2.8.1. Egg albumin induced rat paw edema inflammatory model
- (i)
- where V0 =Volume of oedema at time zero (initial time); VT = Volume of oedema at time T (0.5, 1, 2, 3, 4 and 5h)Average inflammation = (VT-V0)
- (ii)
-
then% inhibition = Average inflammation of control–average inflammation of treated × 100Average inflammation of control
2.8.2. 2% Formaldehyde induced arthritis model
2.8.2.1. Total White blood cell count
2.8.2.2. Differential blood count
3. Results
3.1. pH time dependent analysis
| Liposphere batches (g) | Particle size (µm) | Encapsulation efficiency (EE %) | Loading capacity (LC) | pH time dependence (days) | ||
|---|---|---|---|---|---|---|
| 1 | 7 | 30 | ||||
| 0 | 12.56 ± 2.18 | - | - | 3.5 | 3.5 | 3.5 |
| 2.5 | 26.87 ± 4.21 | 35.2 | 4.4 | 3.8 | 3.8 | 3.8 |
| 5.0 | 42.42 ± 3.64 | 75.6 | 1.89 | 3.8 | 3.9 | 3.9 |
| 7.5 | 82.27 ± 6.24 | 89.4 | 3.4 | 3.7 | 3.9 | 3.9 |
| 10.0 | 98.67 ± 10.23 | 94.1 | 4.7 | 3.7 | 3.8 | 3.8 |
3.2. Encapsulation Efficiency (EE) and Loading capacity (LC)
3.3. Particle size and morphology of lipospheres
3.4. FTIR analysis
3.5. In-vitro anti-inflammatory studies
3.5.1. Membrane stabilization
| Sample (µg/ml) | % inhibition of membrane |
|---|---|
| 50 | 24.60 |
| 100 | 51.70 |
| 200 | 100.0 |
| 400 | 300.0 |
| 800 | 200.0 |
| Aspirin (µg/ml ) | |
| 50 | 89.00 |
| 100 | 5.90 |
| 200 | 100.00 |
| 400 | 100.00 |
| 800 | 106.25 |
3.5.2. Anti-platelet aggregation activity
3.6. In-vivo anti-inflammatory studies
3.6.1. 2% Formaldehyde induced arthritis model
3.6.2. Egg albumin induced rat paw edema inflammatory model
3.6.3. Blood Cells Counts of infected mice
4. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Viana, F.A.; Pouliquen, Y.B.M.; Andrade-Neto, M.; Santiago, G.M.P.; Pessoa, O.D.L.; Rodrigues-Filho, E.; Braz-Filho, R. Complete1H and13C NMR assignments for two new monodesmoside saponins fromPentaclethra macroloba(Willd.) Kuntze. Org. Magn. Reson. 2004, 42, 695–699. [Google Scholar] [CrossRef] [PubMed]
- Pertuit, D.; Kapundu, M.; Mitaine-Offer, A.-C.; Miyamoto, T.; Tanaka, C.; Delaude, C.; Lacaille-Dubois, M.-A. Triterpenoid Saponins From the Stem Bark of Pentaclethra eetveldeana. Nat. Prod. Commun. 2019, 14, 1–5. [Google Scholar] [CrossRef]
- Babady-Byla, Herz W. Triterpenes and 1-(ω-hydroxyceratyl) glycerols from Pentaclethra eetveldeana root bark. Phytochemistry. 1996; 42(2):501-504. [CrossRef]
- Viana, F.A.; Braz-Filho, R.; Pouliquen, Y.B.M.; Net, M.A.; Santiago, G.M.P.; Rodrigues-Filho, E. Triterpenoid saponins from stem bark of Pentaclethra macroloba. J. Braz. Chem. Soc. 2004, 15, 595–602. [Google Scholar] [CrossRef]
- Chinaka C. Nnennaya, Garuba A. Sunday and Augustine A. Ahmadu. Chemical Constituents from the Stem Bark of Pentaclethra macrophylla Benth (Fabaceae). Nig.J.Pharm. Res. 2017; 13 (1):37-44.
- Folefoc GN, Bisseck JP, Fomum ZT and Bodo B. A new Secokaurane diterpenoid and O-glucoside from seeds of Pentaclethera macrophylla. J Cameroon Academy of Science 2004; 4(3): 227-231.
- Akindahunsi, A. A. (2004). Physicochemical studies on African oil bean (Pentaclethra macrophylla Benth.) seed. Journal of Food Agriculture and Environment, 2: 14 - 17.
- Asoegwu S, Ohanyere S., Kanu O.and Iwueke C. “Physical Properties of African Oil Bean Seed (Pentaclethra macrophylla)” Agricultural Engineering International: the CIGR Ejournal. Manuscript FP 05 006. Vol. VIII. August, 2006.
- Novel Anti-Ulcer Phytosomal Formulation of Ethanol Extract of Pentaclethra macrophylla Stem-Bark. Trop. J. Nat. Prod. Res. 2020, 4, 385–391. [CrossRef]
- Igbe, I.; Osigwe, C. Hypoglycaemic activity of aqueous extract of Pentaclethra macrophylla Benth. (Fabaceae) stem bark in streptozotocin-induced diabetic rats. J of Pharmacy and Bioresources 201, 9, 39–44. [Google Scholar]
- Ukoro, B.; Chike, C.P.R.; Olorunfemi, O.J. Effects of Aqueous Extract of Pentaclethra macrophylla Leaves on Blood Pressure and Oxidative Stress in Albino Wistar Rats. International Journal of Scientific Research and Engineering Development 2020, 3. [Google Scholar]
- Iwu, I.C.; Uchegbu, R. Isolation and characterization of 4, 15- Cholestene-3-benzoate from the stem bark of Pentaclethra macrophylla (P. Benth). International Journal of Emerging Knowledge 2014, 1, 185–192. [Google Scholar]
- Tico Etnobotanical Dictionary. 2005. Pentaclethra macrophylla (Benth). Available online: http://www.ars-grin.gov/duke/dictionary/tico/p.html.
- Okunrobo, L. O.; Ching, F. P.; Ifijeh, F. Antinociceptive activity of methanol extract and aqueous fraction of the stem bark of Pentaclethra macrophylla Benth (Mimosaceae). Journal of Medicinal Plants Research 2009, 3, 101–104. [Google Scholar]
- Chidozie JI. African oil bean seed as an essential food supplement in the control of cancer and tobacco related diseases. Proceedings from the U1CC World Cancer Congress, July 8-12, Washington DC, 2006. 8 July.
- Balogun, B.I. Evaluation of the Nutritional Potentials of Fermented Oil Beans Seed Pentaclethra macrophyllah Benth. PAT 2013, 9, 73–87. [Google Scholar]
- Akah, P.A.; Aguwa, C.N.; Agu, R.U. Studies on the antidiarrhoeal properties ofPentaclethra macrophylla leaf extracts. Phytotherapy Res. 1999, 13, 292–295. [Google Scholar] [CrossRef]
- Alinnor, I.; Oze, R. Chemical Evaluation of the Nutritive Value of Pentaclethra macrophylla benth (African Oil Bean) Seeds. Pak. J. Nutr. 2011, 10, 355–359. [Google Scholar] [CrossRef]
- Osabor, VN, Pkpnkwo, PC and Ikeuba AI. Chemical profile of leaves and seeds of Pentaclethra macrophylla Benth. J Medinal Plant and Herbal Therapy Research 2017, 5, 11–17.
- Githens, TS. African Handbooks – Drug Plants of Africa. University of Pennsylvania Press. 1948: P. 64.
- Nnamani, P.; Ibezim, E.; Attama, A.; Adikwu, M. Surface modified solid lipid microparticles based on homolipids and Softisan® 142: preliminary characterization. Asian Pac. J. Trop. Med. 2010, 3, 205–210. [Google Scholar] [CrossRef]
- Yesmin, S.; Paul, A.; Naz, T.; Rahman, A.B.M.A.; Akhter, S.F.; Wahed, M.I.I.; Bin Emran, T.; Siddiqui, S.A. Membrane stabilization as a mechanism of the anti-inflammatory activity of ethanolic root extract of Choi (Piper chaba). Clin. Phytoscience 2020, 6, 1–10. [Google Scholar] [CrossRef]
- Sur T. K, Biswas T. K., Ali L., Mukherjee B. Anti-inflammatory and anti-platelet aggregation activity of human placental extract. Acta Pharmacol Sin 2003, 24, 187–192.
- Zheng, Y.-Y.; Wu, T.-T.; Hou, X.-G.; Gao, Y.; Chen, Y.; Yang, Y.-N.; Li, X.-M.; Ma, X.; Ma, Y.-T.; Xie, X. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial. Eur. Hear. J. - Cardiovasc. Pharmacother. 2019, 6, 211–221. [Google Scholar] [CrossRef] [PubMed]
- Nnamani, P.O.; Attama, A.A.; Kenechukwu, F.C.; Ibezim, E.C.; Adikwu, M.U. Pharmacodynamics of Piroxicam from Novel Solid Lipid Microparticles Formulated with Homolipids from Bos indicus. Curr. Drug Deliv. 2013, 10, 645–655. [Google Scholar] [CrossRef] [PubMed]
- Ochei,J.and Kolhatkar,A. Medical LaboratoryScience Theory and Practice. Tata McGraw Hill Publishing Company Limited.New Dell.2008.
- Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: How should you do it and what do the results mean? Br J Pharmacol. 2004;142:231–55. [CrossRef]
- Chaitanya R, Sandhya S, Banji D, Ravindran V and Murali S. “HRBC Membrane Stabilizing Property of Root, Stem and Leaf of Glochidion elutinum”. International Journal of Research in Pharmaceutical and Biomedical Sciences 2.1 (2011): 256-259.
- Shinde UA, Phadke AS, Nair AM, Mungantiwar AA, Dikshit VJ, Saraf MN. Membrane stabilizing activity — a possible mechanism of action for the anti-inflammatory activity of Cedrus deodarawood oil.Fitoterapia.2008;70:251–7.
- Serafini, M.; Peluso, I.; Raguzzini, A. Flavonoids as anti-inflammatory agents. Proc. Nutr. Soc. 2010, 69, 273–278. [Google Scholar] [CrossRef]
- Beknal AK, Korwar PG, Halkai M, Kulkarni U, Patil BS, Soodam SR. Phytochemical investigation and antioxidant activity study of Drynaria quercifolia Linn. rhizome. Int J Curr Pharmaceut Res. 2010;4:36–9.
- Shah, B. H., Safdar, B., Virani, S. S., Nawaz, Z., Saeed, S. A. & Gilani, A. H. The anti-platelet aggregatory activity of Acacia nilotica is due to blockade of calcium influx through membrane calcium channels. Gen Pharmacol. 1997;29(2): 251-5. [CrossRef]
- Masafumi, Z., Yuhei, H., Shinji, N., Muneaki, M., Ichiro, F. & Eiichi, I. Thromboxane synthesis is increased by upregulating of cytosolic phospholipase A2 and cyclooxygenase-2 in peripheral polymorphonuclear leucocytes during bacterial infection in childhood. Am J Haematol 2003; 72 (2): 115-20. [CrossRef]
- Farrukh, M.; Saleem, U.; Qasim, M.; Manan, M.; Shah, M.A. Sarcococca saligna extract attenuates formaldehyde-induced arthritis in Wistar rats via modulation of pro-inflammatory and inflammatory biomarkers. Inflammopharmacology 2022, 30, 579–597. [Google Scholar] [CrossRef]


| PM Batches (g) | Goat fat (g) | Phospholipon 90H (g) | Sorbitol (g) | Sorbic acid (g) | Tween 80 (g) | Distilled water (qs) w/w |
|---|---|---|---|---|---|---|
| 0 | 0.5 | 0.75 | 4 | 0.05 | 1.5 | 100 |
| 2.5 | 0.5 | 0.75 | 4 | 0.05 | 1.5 | 100 |
| 5.0 | 0.5 | 0.75 | 4 | 0.05 | 1.5 | 100 |
| 7.5 | 0.5 | 0.75 | 4 | 0.05 | 1.5 | 100 |
| 10.0 | 0.5 | 0.75 | 4 | 0.05 | 1.5 | 100 |
| Sample (µg/ml) | Change 1 | Change 2 | Change 3 | Change 4 |
|---|---|---|---|---|
| Mean ± SEM | Mean ± SEM | Mean ± SEM | Mean ± SEM | |
| 50 | 0.007 ± 0.0025cd | 0.0043 ± 0.0013bc | 0.0017 ± 0.0007bc | 0.001 ± 0.00b |
| 100 | 0.004 ± 0.001abcd | 0.0047 ± 0.0017bc | 0.005 ± 0.0021ab | 0.0037 ± 0.002a |
| 200 | 0.0013 ± 0.009ab | 0.002 ± 0.0006ab | 0.007 ± 0.0026a | 0.0023 ± 0.009b |
| 400 | 0.0017 ± 0.002ab | 0.0033 ± 0.0007bc | 0.0007 ± 0.0003c | 0.0057 ± 0.002a |
| 800 | 0.000 ± 0.00a | 0.000 ± 0.00a | 0.00 ± 0.00c | 0.001 ± 0.001b |
| Aspirin (µg/ml ) | ||||
| 50 | 0.005 ± 0.001abcd | 0.0063 ± 0.0018c | 0.0023 ± 0.009bc | 0.002 ± 0.006b |
| 100 | 0.0033 ± 0.0007abc | 0.002 ± 0.0006ab | 0.0010 ± 0.00c | 0.0010 ± 0.006b |
| 200 | 0.004 ± 0.0021abcd | 0.003 ± 0.001abc | 0.003 ± 0.00bc | 0.0013 ± 0.0007b |
| 400 | 0.0057 ± 0.002bcd | 0.0043 ± 0.0015abc | 0.0027 ± 0.0007bc | 0.0013 ± 0.0003b |
| 800 | 0.009 ± 0.0012d | 0.0067 ± 0.0015c | 0.0027 ± 0.0007bc | 0.0023 ± 0.0009b |
| Treatments (mg/kg) | Volume of Edema (ml) (Percentage inhibition of Edema) over time (h) | ||||||
|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | 48 | |
| T50 | 0.375 ± 0.025 | 0.750 ± 0.029 (0.00) |
0.650 ± 0.029 a (7.14) |
0.525 ± 0.025 a (0.00) |
0.500 ± 0.00 b (16.7) |
0.500 ± 0.00 b (0.00) |
0.425 ± 0.048 (-6.2) |
| T100 | 0.300 ± 0.00 | 0.700 ± 0.00 (6.7) |
0.600 ± 0.00 b (14.3) |
0.525 ± 0.025 a (0.00) |
0.525 ± 0.025 b (12.5) |
0.475 ± 0.025 c (0.00) |
0.400 ± 0.00 (0.00) |
| T150 | 0.325 ± 0.025 | 0.675 ± 0.025 (10.0) |
0.575 ± 0.025 b (17.8) |
0.525 ± 0.025 a (0.00) |
0.525 ± 0.025 b (12.5) |
0.500 ± 0.00 b (0.00) |
0.425 ± 0.025 (-6.25) |
| T200 | 0.325 ± 0.025 | 0.725 ± 0.025 (3.33) |
0.600 ± 0.00 b (14.29) |
0.500 ± 0.00 b (4.8) |
0.525 ± 0.025 b (12.5) |
0.550± 0.029 b (10.0) |
0.425 ± 0.025 (-6.25) |
| PC | 0.325 ± 0.025 | 0.70 ± 0.04 (6.7) |
0.60 ± 0.04 b (6.7) |
0.50 ± 0.041 b (4.77) |
0.475 ± 0.00 b (21.0) |
0.40 ± 0.00 a (20.0) |
0.40 ± 0.00 (0.00) |
| NC | 0.30 ± 0.00 | 0.75 ± 0.041 | 0.70 ± 0.029 a | 0.525 ± 0.025 a | 0.60 ± 0.00 a | 0.50 ± 0.00 b | 0.40 ± 0.00 |
| Normal | 0.35 ± 0.05 | 0.75 ± 0.05 | 0.65 ± 0.00 a | 0.60 ± 0.00 a | 0.5 ± 0.025 b | 0.475 ± 0.025 c | 0.40 ± 0.00 |
| Treatments (mg/kg) | Volume of Edema (ml) (Percentage inhibition of Edema) over time (h) | |||||
|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | |
| T50 | 0.350 ± 0.029 | 0.625 ± 0.025 (-4.17) |
0.550 ± 0.029 abc (-4.7) |
0.500 ± 0.058 a (-17.65) |
0.475 ± 0.048 a (-15.79) |
0.650 ± 0.029 a (-8.33) |
| T100 | 0.275 ± 0.025 | 0.625 ± 0.025 (-4.17) |
0.600 ± 0.00 ab (-14.29) |
0.525 ± 0.025 a (-23.5) |
0.525 ± 0.025 b (-31.25) |
0.650 ± 0.029 a (-4.17) |
| T150 | 0.300 ± 0.00 | 0.500 ± 0.00 (16.6) |
0.500 ± 0.058 c (4.76) |
0.433 ± 0.033 b (-1.88) |
0.433 ± 0.33 a (-8.25) |
0.633 ± 0.033 a (-5.5) |
| T200 | 0.267 ± 0.033 | 0.600 ± 0.058 (0.00) |
0.533 ± 0.033 ac (-1.5) |
0.500 ± 0.00 a (-17.64) |
0.533 ± 0.033 b (-33.25) |
0.700 ± 0.00 a (-6.0) |
| PC | 0.30 ± 0.00 | 0.625 ± 0.025 (4.17) |
0.500 ± 0.00 c (4.76) |
0.425 ± 0.025 b (0.00) |
0.425 ± 0.025 a (-6.25) |
0.600 ± 0.00 b (0.00) |
| NC | 0.30 ± 0.00 | 0.6 ± 0.00 | 0.525 ± 0.025 b | 0.425 ± 0.029 a | 0.400 ± 0.00 a | 0.60 ± 0.00 a |
| Normal | 0.275 ± 0.025 | 0.55 ± 0.029 | 0.625 ± 0.025 ac | 0.575 ± 0.025 b | 0.50 ± 0.041 a | 0.65 ± 0.029 b |
| Treatments (mg/kg) | Blood Cell Count (%) | |||||
|---|---|---|---|---|---|---|
| WBC | Neutrophil | Lymphocytes | Eosinophil | Monocyte | Basophil | |
| T50 | 77.50 ± 3.59 | 65.50 ± 1.50 bc | 34.00 ± 1.414 abc | 0.50 ± 0.5 | 0.00 | 0.00 |
| T100 | 70.00 ± 1.83 | 58.50 ± 1.71 a | 40.00 ± 1.63 c | 1.50 ± 0.5 | 0.00 | 0.00 |
| T150 | 70.50 ± 1.71 | 61.50 ± 1.71 abc | 37.50 ± 2.22 abc | 1.00 ± 0.57 | 0.00 | 0.00 |
| T200 | 67.50 ± 3.50 | 61.00 ± 1.29 b | 38.50 ± 0.96 bc | 0.50 ± 0.5 | 0.00 | 0.00 |
| PC | 71.00 ± 3.512 | 63.50 ± 3.403 abc | 36.00 ± 3.747 abc | 0.50 ± 0.50 | 0.00 | 0.00 |
| NC | 67.00 ± 2.646 | 67.25 ± 0.479 c | 31.00 ± 0.577 a | 1.75 ± 0.629 | 0.00 | 0.00 |
| Normal 1 | 72.00 ± 4.320 | 61.50 ± 1.50 abc | 36.50 ± 0.751 abc | 2.0 ± 0.816 | 0.00 | 0.00 |
| Normal 2 | 68.80 ± 2.062 | 65.00 ± 1.915 bc | 32.00 ± 1.414 ab | 2.50 ± 0.500 | 0.00 | 0.00 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).